News & field notes
News
Catch up on the latest from Newert
EmoConnect PPG&Motion Successfully Obtains FCC and CE Certifications
EmoConnect PPG&Motion, a biosignal measurement device for research and development independently developed by Newert Co., Ltd., has obtained both FCC certification in the United States and CE certification in Europe.With this achievement, EmoConnect PPG&Motion, following its existing KC certification, has now been officially recognized for its technical compliance in major global markets, establishing an important stepping stone for expansion into the global market beyond China.FCC certification
Newert Selected for the Youth Startup Incubation Program
Newert has been selected for the "Youth Startup Incubation" program run at Incheon Startup Park by Incheon Technopark (Incheon TP) and the Incheon Free Economic Zone Authority. The program identifies promising youth startups recommended by startup support organizations in the Incheon region and, together with the accelerator Kingo Spring, helps them attract investment and build a foundation for sustainable growth. Fifteen companies were selected, all led by founders aged 39 or under.
Newert Joins the Inha University Hospital Open Laboratory Program
Newert has been selected for the "2025 Open Laboratory Operation Program," which supports the growth of startups holding strong technologies and products by opening up the resources of Inha University Hospital. Newert will use the hospital's infrastructure with EmoConnect PPG&Motion to secure clinical data on biosignal measurement across skin tones and to advance the technology through expert advice on the biomarkers needed in the field.
Newert Certified at 98% Heart Rate (HR) Measurement Accuracy
To objectively verify the accuracy of the heart rate (HR) data produced by "EmoConnect PPG&Motion," Newert's wristband-type biosignal measurement device, the company commissioned performance testing at the Korea Testing Certification (KTC), one of Korea's leading testing and certification institutes. The test used the AECG100 Wearable Device Tester in line with IEC 63203-402-3:2024, the latest international standard defining heart rate accuracy test methods for wearable devices. The result was 98% accuracy, officially confirming the reliability of "EmoConnect PPG&Motion."
Newert Selected for Incheon Regional Specialization (Bio/Medical) Startup Success Package Commercialization Support
Newert has been selected under the "Incheon Regional Specialization (Bio and Medical)" track of the "Startup Success Package (Youth Startup Academy) Commercialization Support" program operated by the Korea SMEs and Startups Agency. Project: a wearable biosignal measurement system with smart filtering (EmoConnect). Building on this, the company plans to expand promotion and marketing and lay the groundwork for global commercialization from 2025.
Newert Selected for the Win-Win Startup and Venture Support Program
Newert has been selected for the "2024 Win-Win Startup and Venture Company Support Program," run by the Korea Power Exchange to accelerate the growth and global expansion of startups and venture companies. Program name: Korea Power Exchange Win-Win Startup and Venture Company Support Program. Agreement period: 2024.11.22 – 2025.02.28
Newert Completes Venture Company Certification
As a company with the expertise to operate in the biosignal research industry, Newert has completed its registration and certification as a venture company under Article 25 of the Venture Business Act.
EmoConnect PPG&Motion Completes KC Certification
"EmoConnect PPG&Motion," the proprietary biosignal measurement device and software researched and developed by Newert, has completed KC certification under Article 58(2) of the Electronics Act and will reach the market soon. [About EmoConnect PPG&Motion] A smart-band wearable that applies smart filtering technology to keep raw-data collection stable where the signal would otherwise be distorted, providing equipment and technology specialized for daily lifestyle management and health-improvement training in digital healthcare.
Newert Completes Registration and Certification as a Specialized Research Business
As a company with the expertise to operate in the biosignal research industry, Newert has completed its registration and certification as a Specialized Research Business under Article 6(1) of the Research Industry Promotion Act.
Newert Completes Manufacturing Business Registration
Newert has signed a manufacturing consignment agreement with a specialist partner to produce biosignal measurement devices, and has completed its manufacturing business registration under the category of other medical devices.
Newert Selected for the SME IP (Intellectual Property) Direct Support Program
Newert has been selected for the "2024 SME IP (Intellectual Property) Direct Support" program, organized by the Intellectual Property Center to provide SMEs with tailored IP services covering design, brand development, patented technology, and domestic and overseas filings.